DEPARTMENT OF HUMAN SERVICES

Meeting Minutes: Drug Formulary Committee (DFC) - DRAFT

Date and Time: December 17, 2025: 9:15a.m. – 1:30 p.m. (Central Time)
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2360

Attendance

- Members in attendance: Arthur Beisang, MD; Jacques Beasley; Mary Mescher Benbenek, PhD, APRN; Jeannine Conway, PharmD; Emily Jaeger, PharmD; Katherine Montag Schafer, PharmD; Emma Ryan, PharmD; Kelly Ruby, PharmD; Sheila Scheuer, PharmD; Julie Wolfgram, DNP, FNP; Stuart Williams, JD
- Members absent: Margaret Artz, RPh, PhD; Jena Wirt, DO; Romie Tinsay, MD; Sandra Widhalm Murphy, RPh
- DHS staff present: Chad Hope, PharmD; Dave Hoang, PharmD, MBA; Aaron Drake, RPh; Erin Neumann, PharmD; Nikki Thompson, DHS Ethics Officer
- Others in attendance: Naana Osei-Boateng, PharmD; Chloe Groomes, PharmD; Andrew Wherley, PharmD; Laura Pounders, PharmD

Report of the Chair

- Stuart Williams presided over the meeting. New member Jeannine Conway was introduced and welcomed to the DFC.
- There are a number of open vacancies on the DFC. The chair proposed nominations and voting of new chair and vice-chair be deferred until the first meeting of the DFC in 2026.

Approval of Minutes

- The DFC approved the minutes from the September 2025 meeting.

DHS Housekeeping

- Nikki Thompson, DHS Ethics Officer, provided an overview of conflict-of-interest policy and practice for the DFC.
- Dave Hoang, DFC Coordinator, announced the retirements of long-standing DFC members Margaret Artz, RPh, PhD and Monica Brands, RPH and acknowledged their service and commitment to the work of the DFC.

Old Business

- None

New Business

- None

Specialty Drugs for Continued PA

- The committee discussed Zelsuvmi and recommended to DHS by a unanimous vote that Zelsuvmi remain on PA with the following amendment to the proposed criteria:
    - Initial approval criteria, bullet point #3 to be removed.

- The committee discussed Sephience and recommended to DHS by a unanimous vote that Sephience remain on PA with the proposed criteria:

- The committee discussed Orlynvah and recommended to DHS by a unanimous vote that Orlynvah remain on PA with the proposed criteria.

- The committee discussed Brinsupri and recommended to DHS by a unanimous vote that Brinsupri remain on PA with the following amendment to the proposed criteria:
    - Initial approval criteria, bullet point #2, sub-bullet #4 be changed to: "Patient has had at least ~~two~~ *one* pulmonary exacerbations…"

- The committee discussed Casgevy and recommended to DHS by a unanimous vote that Casgevy remain on PA with the proposed criteria and recommended the product be reviewed again in 6 months

CONSENT AGENDA ITEMS:

The committee discussed and recommended by a unanimous vote that all proposed PA criteria for various drugs in the Consent Agenda Items be approved as presented.

Preferred Drug List (PDL) Review

CONSENT AGENDA ITEMS:

The committee discussed and recommended by a unanimous vote that all classes in the Consent Agenda Items be approved as presented with no changes.

DISCUSSION ITEMS:

- The committee discussed the Acne Agents, Topical therapeutic class and recommended the following to the department by a unanimous vote:

    - ADAPALENE GEL OTC (TOPICAL) added to the PDL to as PREFERRED.
    - TRETINOIN CREAM (TOPICAL) and TRETINOIN GEL (AVITA, RETIN-A) (TOPICAL) to be moved on the PDL to PREFERRED.

- BP 10-1 (TOPICAL), OVACE PLUS CREAM ER (TOPICAL), OVACE PLUS SHAMPOO (TOPICAL), to be removed from the PDL.

- The committee discussed the Anticonvulsants, Other therapeutic class and recommended the following to the department by a unanimous vote:
    - ESLICARBAZEPINE (ORAL) and PERAMPANEL TABLET (ORAL) to be added to the PDL as NONPREFERRED.
    - FYCOMPA TABLET DOSE PACK (ORAL), MYSOLINE (ORAL) and VIMPAT TABLET DOSE PACK (ORAL) to be removed from the PDL.

- The committee discussed the Bone Resorption Suppression and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - BILDYOS (SUBCUTANE.), BILPREVDA (SUBCUTANE.), BOMYNTRA (SUBCUTANE.), BONSITY (SUBCUTANE.), CONEXXENCE (SUBCUTANE.), JUBBONTI (SUBCUTANE.), OSENVELT (SUBCUTANE.), STOBOCLO (SUBCUTANE.), WYOST (SUBCUTANE.) and XGEVA (SUBCUTANE.) to be added to the PDL as NONPREFERRED.
    - FORTICAL (NASAL) to be removed from the PDL.

- The committee discussed the Cytokine and CAM Antagonists therapeutic class and recommended the following to the department by a unanimous vote:
    - PYZCHIVA VIAL (SUBCUTANE.), PYZCHIVA SYRINGE (SUBCUTANEOUS), PYZCHIVA VIAL (INTRAVENOUS), STEQEYMA SYRINGE (SUBCUTANE.) and STEQEYMA VIAL (INTRAVENOUS) to be added to the PDL as PREFERRED.
    - ADALIMUMAB-ADBM SYRINGE (SUBCUTANE.), ADALIMUMAB ADBM PEN (SUBCUTANE.), CYLTEZO SYRINGE (SUBCUTANE.), CYLTEZO PEN (SUBCUTANE.), YESINTEK SYRINGE (SUBCUTANE.) and YESINTEK VIAL (SUBCUTANE.) to be moved on the PDL to PREFERRED.
    - ADALIMUMAB-ADBM SYRINGE, (QUALLENT)(SUBCUTANE.) ADALIMUMAB ADBM PEN, (QUALLENT)(SUBCUTANE.), AVTOZMA (INJECTION), IMULDOSA SYRINGE (SUBCUTANE.), IMULDOSA VIAL (INTRAVENOUS), OTEZLA XR (ORAL), OTULFI SYRINGE (SUBCUTANEOUS), OTULFI VIAL (INTRAVENOUS), SELARSDI SYRINGE (SUBCUTANE.), SELARSDI VIAL (INTRAVENOUS), USTEKINUMAB SYRINGE (SUBCUTANE), USTEKINUMAB VIAL (INTRAVENOUS), USTEKINUMAB VIAL (SUBCUTANE), USTEKINUMAB -AEKN SYRINGE (SUBCUTANE.), USTEKINUMAB -TTWE VIAL (QUALLENT) (INTRAVENOUS) and USTEKINUMAB -TTWE SYRINGE (QUALLENT) (SUBCUTANE.) to be added to the PDL as NONPREFERRED.
    - HUMIRA KIT (INJECTION), HUMIRA PEN KIT (INJECTION) to be moved on the PDL to NONPREFERRED.

- The committee discussed the HAE Treatments therapeutic class and recommended the following to the department by a unanimous vote:
    - ANDEMBRY (SUB-Q), DAWNZERA (SUB-Q) and EKTERLY (ORAL) to be to be added to the PDL as NONPREFERRED.

- The committee discussed the Hypoglycemics, Incretin Mimetics/Enhancers therapeutic class and recommended the following to the department by a unanimous vote:
    - BRYNOVIN (ORAL), ZITUVIMET (ORAL) and ZITUVIMET XR (ORAL) to be added to the PDL as NONPREFERRED.

- The committee discussed the PAH Agents, Oral and Inhaled therapeutic class and recommended the following to the department by a unanimous vote:
    - LIQREV SUSPENSION (ORAL) to be removed from the PDL.
    - YUTREPIA (INHALATION) to be added to the PDL as NONPREFERRED.

- The committee discussed the Sedative Hypnotics therapeutic class and recommended the following to the department by a unanimous vote:
    - BELSOMRA (ORAL) and RAMELTEON (ORAL) to be moved on the PDL to PREFERRED
    - DOXEPIN TABLET (ORAL) to be added to the PDL as NONPREFERRED.
    - ROZEREM (ORAL) to be moved on the PDL to NONPREFERRED.

- The committee discussed the Sickle Cell Anemia Treatments therapeutic class and recommended the following to the department by a unanimous vote:
    - XROMI SOLUTION (ORAL) to be added to the PDL as NONPREFERRED.
    - OXBRYTA (ORAL) to be removed from the PDL

- The committee discussed the Stimulants and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - CLONIDINE ER (ORAL) to be added to the PDL as PREFERRED.
    - METHYLPHENIDATE ER (RITALIN LA) (ORAL) to be moved on the PDL to PREFERRED.
    - AMPHETAMINE ER ODT (ORAL) and ONYDA XR SUSPENSION (ORAL) to be added to the PDL as NONPREFERRED.
    - ADHANSIA XR (ORAL) and RITALIN LA (ORAL) to be removed from the PDL.

Other Business

- Members of the DFC were reminded to submit their invoices to the department.
- Member annual conflict-of-interest disclosures are due. Communication will be made via email.

Adjournment

- The meeting was adjourned at approximately 12:06pm Central Time.